Table 2.
Clinical characteristics at baseline.
| Clinical parameter | Number of patients | Median ± interquartile range | ||
|---|---|---|---|---|
| M | F | M | F | |
| Diabetes | 10 | 22 | ||
| CAPD/APD | 53/10 | 27/4 | ||
| Dianeal/Physioneal | 55/8 | 23/8 | ||
| Time on PD (months) | 62 | 31 | 16.80 ± 20.50 | 12.20 ± 21.50 |
| DPCrea4 | 63 | 31 | 0.74 ± 0.14 | 0.70 ± 0.15 |
| Ultrafiltration_PET (mL) | 63 | 31 | 400.00 ± 344.30 | 540.00 ± 398.20 |
| IL-6 (ρg/mL) | 61 | 30 | 96.74 ± 138.87 | 71.16 ± 119.13 |
| IL-8 (ρg/mL) | 60 | 30 | 35.44 ± 93.00 | 19.81 ± 49.25 |
| MCP-1 (ρg/mL) | 61 | 30 | 247.01 ± 178.99 | 171.91 ± 118.38 |
| TGFβ-1 (ρg/mL) | 61 | 30 | 75.05 ± 82.78 | 93.43 ± 77.05 |
| VEGF (ρg/mL) | 60 | 29 | 146.94 ± 114.11 | 102.58 ± 140.27 |
| CA-125 (ρg/mL) | 61 | 30 | 19.60 ± 18.40 | 21.45 ± 13.6 |
| HA (ρg/mL) | 61 | 30 | 179.11 ± 138.27 | 148.52 ± 129.13 |
Given are the numbers of patients (M, male/F, female) with available data on the stated parameter. See Table 1 for total patient number at study month 0. The following clinical parameters were used as confounders for regression analysis with GEE, next to age and sex: Diabetes; CAPD, Continuous Ambulatory Peritoneal Dialysis; APD, Automated Peritoneal Dialysis; Dianeal or Physioneal treatment group; time on PD (refers to the total time in months after a patient was first introduced to PD treatment). The Dianeal group was randomised into two treatment groups at baseline, i.e. 27/11 male/female patients continued with Dianeal for 24 months, while 28/12 male/female patients switched to Physioneal for the following 24 months. DPCrea4 is the ratio of creatinine in the effluent vs. plasma during 4-h dwell time.